<DOC>
	<DOCNO>NCT02199288</DOCNO>
	<brief_summary>This prospective , open-label , multicenter , observational study investigate effectiveness safety MabThera SC ( rituximab , subcutaneous ) induction therapy patient non-Hodgkin 's lymphoma , follow first initial treatment MabThera IV ( rituximab , intraveneous ) . Induction treatment period study estimate 8 month .</brief_summary>
	<brief_title>Effectiveness , Safety &amp; Nurse Management Study MabThera SC Patients With Non-Hodgkin 's Lymphoma : Real-Life Setting</brief_title>
	<detailed_description />
	<mesh_term>Lymphoma</mesh_term>
	<mesh_term>Lymphoma , Non-Hodgkin</mesh_term>
	<mesh_term>Rituximab</mesh_term>
	<criteria>1 . Indication accord Summary Product Characteristics ( SPC ) MabThera SC formulation : As treatment previously untreated patient stage IIIIV follicular lymphoma combination chemotherapy As treatment patient CD20 positive diffuse large B cell nonHodgkin 's lymphoma combination chemotherapy 2 . At least 4 treatment cycle MabThera plan 3 . Patients &gt; /= 18 year inclusion 4 . Patients write informed consent 5 . Treatment decision prescribe MabThera SC take physician prior recruitment study 1 . Contraindications accord SPC MabThera SC formulation : Hypersensitivity active substance murine antibody , hyaluronidase excipients Active severe infection Patients severe immunsuppression 2 . Patient include clinical trial experimental pharmaceutical 3 . Pregnancy</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>November 2016</verification_date>
</DOC>